Index - P/E - EPS (ttm) - Insider Own 51.95% Shs Outstand 31.85M Perf Week -2.08%
Market Cap 734.78M Forward P/E - EPS next Y - Insider Trans 105.64% Shs Float 15.30M Perf Month -
Income - PEG - EPS next Q -2.72 Inst Own 19.45% Short Float 2.38% Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio 1.48 Perf Half Y -
Book/sh -3.07 P/B - EPS next Y - ROA - Short Interest 0.36M Perf Year -
Cash/sh 1.74 P/C 13.30 EPS next 5Y - ROE - 52W Range 20.29 - 26.19 Perf YTD -2.45%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -11.91% Beta -
Dividend TTM - Quick Ratio 7.17 Sales past 5Y 0.00% Gross Margin - 52W Low 13.73% ATR (14) 2.43
Dividend Ex-Date - Current Ratio 7.17 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 11.82% -
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 37.25
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 1.09 Prev Close 21.85
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings Aug 28 Avg Volume 246.04K Price 23.07
SMA20 -0.25% SMA50 -0.25% SMA200 -0.25% Trades
Volume 267,565 Change 5.58%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-08-24 Initiated Stifel
Buy
$40
Oct-08-24 Initiated JP Morgan
Overweight
$30
Oct-08-24 Initiated Jefferies
Buy
$35
Oct-08-24 Initiated Guggenheim
Buy
$44
Sep-30-24 08:00AM
Sep-23-24 07:05PM
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
